# MRI and PET to Assess Pembrolizumab Response

> **NCT02591654** · EARLY_PHASE1 · TERMINATED · sponsor: **Columbia University** · enrollment: 6 (actual)

## Conditions studied

- Malignant Melanoma, Metastatic

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** FLT PET

## Key facts

- **NCT ID:** NCT02591654
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2022-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02591654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02591654, "MRI and PET to Assess Pembrolizumab Response". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02591654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*